India Globalization Capital Inc (IGC)
0.347
+0.01
(+2.03%)
USD |
NYAM |
Mar 20, 12:20
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 18.42M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.52% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 20.78 |
| Price to Book Value | 1.005 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0077 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.85% |
News
Headline
Wire
Time (ET)
MT Newswires
11/01 16:32
MT Newswires
08/08 06:00
SA Breaking News
06/21 06:15
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/04/2023* | -- | Results | Q1 2024 | -- | -- | -- | |
| 08/05/2022 | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/10/2022 | -- | Results | Q3 2022 | -- | -- | -- | |
| 10/29/2021 | -- | Results | Q2 2022 | -- | -- | -- | |
| 08/11/2021 | -- | Results | Q1 2022 | -- | -- | -- | |
| 02/12/2021 | -- | Results | Q3 2021 | -- | -- | -- | |
| 11/20/2020 | -- | Results | Q2 2021 | -- | -- | -- | |
| 08/19/2020 | -- | Results | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental of heavy construction equipment, and the purchase and resale of physical commodities used in infrastructure. The Life Sciences Segment includes biopharmaceuticals and Over the Counter Products Geographically, it derives a majority of revenue from Hong Kong and also has a presence in India. |
| URL | https://www.igcinc.us |
| Investor Relations URL | http://www.igcinc.us/investor-center/overview/ |
| HQ State/Province | Maryland |
| Sector | Industrials |
| Industry | Conglomerates |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 04, 2023 (est.) |
| Last Earnings Release | Aug. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 17, 2023.
Fundamentals
| Revenue (TTM) | 0.868M |
| Total Expenses (TTM) | 14.94M |
| Net Income (TTM) | -13.98M |
| Total Assets (Quarterly) | 20.07M |
| Total Liabilities (Quarterly) | 1.753M |
| Shareholders Equity (Quarterly) | 18.32M |
| Cash from Operations (TTM) | -6.417M |
| Cash from Investing (TTM) | -0.546M |
| Cash from Financing (TTM) | 0.10M |
Ratings
Profile
Edit
| India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental of heavy construction equipment, and the purchase and resale of physical commodities used in infrastructure. The Life Sciences Segment includes biopharmaceuticals and Over the Counter Products Geographically, it derives a majority of revenue from Hong Kong and also has a presence in India. |
| URL | https://www.igcinc.us |
| Investor Relations URL | http://www.igcinc.us/investor-center/overview/ |
| HQ State/Province | Maryland |
| Sector | Industrials |
| Industry | Conglomerates |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 04, 2023 (est.) |
| Last Earnings Release | Aug. 05, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| IGC Tweets |